

Amendments to the Specification:

Please replace the paragraph beginning at page 4, line 7, with the following rewritten paragraph:

-- Preferred effectors for DP IV, are for example, Xaa-Pro-dipeptides, corresponding derivatives, preferably dipeptide phosphonic acid diaryl esters and their salts, dipeptide boronic acids (e.g. Pro-boro-Pro) and their salts, Xaa-Xaa-(Trp)-Pro-(Xaa)_n peptides (n = 0 to 10), corresponding derivatives and their salts or amino acid (Xaa)-amides, corresponding derivatives and their salts, wherein Xaa is an α -amino acid/imino acid or an α -amino acid derivative/imino acid derivative, preferably N^ε-4-nitrobenzyl oxycarbonyl-L-lysine, L-proline, L-tryptophane, L-isoleucine, L-valine, and cyclic amines, e.g. pyrrolidine, piperidine, thiazolidine, and their derivatives act as amide structure, tryptophane-1,2,3,4-tetrahydroisochinoline-3-carboxylic acid derivatives (TSL) and/or (2S,2S',2S'')-2-[2'-[2''-amino-3''-(indol-3'''-yl)-1''-oxopropyl]-1',2',3',4'-tetrahydro-6'8'-dihydroxy-7-methoxyisochinol-3-yl-carbonyl-amino]-4-hydromethyl-5-hydropentanoic acid (TMC-2A). Such compounds and their preparation were described in an earlier patent (K. Neubert et al. DD 296075A5). Preferred inhibitors for the alanyl amino peptidase are actinonin, bestatin (ubenimex), probestin, phebestin, RB3014, leuhistin, amastatin, β -aminothiols, α -aminophosphinic acids, α -amino phosphinic acid derivatives, preferably D-Phe- ψ -[PO(OH)-CH₂]-Phe-Phe.--

Please replace the paragraph beginning at page 4, line 17, with the following rewritten paragraph:

The inhibitors or pharmaceutical compositions containing them are administered simultaneously with known carrier

substances. On the one hand, the administration occurs as a topical application in the form of, for example, creams, ointments, pastes, gels, solutions, sprays, liposomes and nanosomes, lotions (agitated mixtures), hydrocolloid dressings, plasters and similar novel carrier substrates, jet injections or other dermatological bases/vehicles, including instillative applications, and on the other hand, as a systemic application for oral, transdermal, intravenous, subcutaneous, intracutaneous, intramuscular use in suitable formulations or in a suitable galenic form.